Agents against common colds, SARS and other coronaviral diseases
Human coronaviruses (HcoV) are the major cause of diseases of the upper respiratory tract in humans. Apart from the common cold these include e.g. the life-threatening severe acute respiratory syndrome (SARS), that, originating in China, has appeared in other parts of the world with a mortality rate of 15%. A key enzyme for the replication cycle of the coronavirus is the HcoV proteinase Mpro. The functional relevance of Mpro makes it an attractive target for the development of drugs against SARS and other coronaviral diseases.
The present invention relates to a group of anticoronaviral agents whose functional mechanism is based on the specific blockade of the substrate binding site of HCoV Mpro. In vitro test systems have shown the substances according to the invention to be highly effective against several coronaviruses.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Retinoblastoma: Eye-Catching Investigation into Retinal Tumor Cells
A research team from the Medical Faculty of the University of Duisburg-Essen and the University Hospital Essen has developed a new cell culture model that can be used to better…
A Job Well Done: How Hiroshima’s Groundwater Strategy Helped Manage Floods
Groundwater and multilevel cooperation in recovery efforts mitigated water crisis after flooding. Converting Disasters into Opportunities Society is often vulnerable to disasters, but how humans manage during and after can…
Shaping the Future: DNA Nanorobots That Can Modify Synthetic Cells
Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of “DNA origami”. The system they developed may facilitate the…